EKF Diagnostics Holdings plc (EKDHF)

Market Cap	123.93M
Revenue (ttm)	62.84M
Net Income (ttm)	7.81M
Shares Out	n/a
EPS (ttm)	0.02
PE Ratio	15.86
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	3,665
Open	0.2474
Previous Close	n/a
Day's Range	0.2474 - 0.2474
52-Week Range	0.3131 - 0.3958
Beta	0.47
RSI	36.48
Earnings Date	Jun 17, 2025

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucos...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 317
• Stock Exchange: OTCMKTS
• Ticker Symbol: EKDHF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.

Financial numbers in GBP